Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Food and Drug Administration (2011) Full prescribing information: Zytiga™ (abiraterone acetate) tablet. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf
2. Aleksovski A, Dreu R, Gašperlin M, Planinšek O (2015) Mini-tablets: a contemporary system for oral drug delivery in targeted patient groups. Expert Opin Drug Deliv 12(1):65–84
3. Alshora DH, Ibrahim MA, Alanazi FK (2016) Nanotechnology from particle size reduction to enhancing aqueous solubility. Surface chemistry of nanobiomaterials. Elsevier, Oxford, pp 163–191
4. Balakrishnan A, Rege BD, Amidon GL, Polli JE (2004) Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. J Pharm Sci 93(8):2064–2075
5. Basa-Dénes O, Solymosi T, Ötvös Z, Angi R, Ujhelyi A, Jordán T, Glavinas H (2019) Investigations of the mechanism behind the rapid absorption of nano-amorphous abiraterone acetate. Eur J Pharm Sci 129:79–86